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Abstract— Data-mining techniques have frequently been de-
veloped for Spontaneous reporting databases. These techniques
aim to find adverse drug events accurately and efficiently. Spon-
taneous reporting databases are prone to missing information,
under reporting and incorrect entries. This often results in a
detection lag or prevents the detection of some adverse drug
events. These limitations do not occur in electronic health-
care databases. In this paper, existing methods developed for
spontaneous reporting databases are implemented on both a
spontaneous reporting database and a general practice elec-
tronic health-care database and compared. The results suggests
that the application of existing methods to the general practice
database may help find signals that have gone undetected when
using the spontaneous reporting system database. In addition
the general practice database provides far more supplementary
information, that if incorporated in analysis could provide
a wealth of information for identifying adverse events more
accurately.
I. INTRODUCTION
The importance of data-mining techniques that could iden-
tify potential adverse drug events (ADEs) by analyzing infor-
mation contained in large electronic medical databases was
recognized decades ago. The more available type of medical
database, namely the spontaneous reporting system (SRS)
database, often contains records for thousands of suspected
adverse events. In SRS databases there is a connection in
the database between any drug and suspected adverse event
that is reported. The main problems that SRS databases
face are incomplete or incorrect records, limited information
and under-reporting [9]. Existing data-mining techniques
include the reporting odds ratio (ROR)[12], the proportional
reporting ratio (PRR)[6], the bayesian confidence propaga-
tion neural network (BCPNN)[2] and the multi-item gamma
poisson shrinker (MGPS) [5]. These techniques have been
developed specifically for use with the SRS databases. They
make use of the limited information by finding drug and
adverse event associations that are disproportional relative to
the rest of the drugs and events contained in the database.
A different type of medical database, referred to in this
paper as the general practice (GP) database, contains the
electronic records from a UK general practice. GP databases
contain a greater depth of information for a patient, including
details of all prescribed medications while the patient is
registered. In general practice databases there are no direct
drug and ADE connections. These can only be predicted by
looking for events that occur for a set time period after a
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Drug of interest Other drugs
Event of interest a b
Other event c d
TABLE I
STATISTICAL SIGNIFICANCE IN SRS DATABASES ARE OFTEN
CALCULATED USING THE FREQUENCIES a, b, c, d ∈ Z≥0 .
drug is taken. However, events that occur after a drug is taken
may be linked to the cause of taking the drug, may be age
related or be seasonal effects. This difference between the
database structures may prevent the existing methods from
being effective. Nevertheless, if the existing methods can be
applied to the GP database successfully, this may enable the
identification of real signals that were missed from the SRS
databases due to incorrect records and under-reporting.
Recently there has been a focus on combining both the
SRS and GP databases for signal detection [4]. Little research
has focused on developing or implementing an effective and
efficient method for signal detection only on a GP database.
In this paper the application of existing data-mining tech-
niques, developed for the SRS database, to the GP database
will be investigated. The ROR and PRR are implemented as
these methods are more efficient when investigating a single
drug. It has been shown in the past that if each drug-ADE
has a frequency of four or more, all the methods have fairly
similar results [13]. As there is currently no golden standard
for the SRS data-mining techniques, drugs with known side
effects will be used for the investigation.
In the next section the standard data mining methods
used in this paper are outlined along with an explanation
of a data transformation approach that is used in order to
make the GP database usable by the standard methods. A
technique for comparing the obtained results, namely the
receiver operating characteristic analysis, is then described.
Subsequently a summary of the results obtained by the
application of the existing methods on the GP and the SRS
databases is presented. The paper concludes with a discussion
of the obtained results and possible future work that warrants
investigation due to our attained findings.
II. METHODS
In this work we are interested in comparing two of the
standard techniques, namely the reporting odds ratio (ROR)
and proportional reporting ratio (PRR) on two different
datasets. Both methods use the values according to a 2 ×
2 contingency table, shown in Table I.
A. Reporting Odds Ratio
ROR is a ratio of two other ratios. It can be denoted as
follows:
ROR =
a/b
c/d
(1)
where values a, b, c, d are calculated according to Table I.
The value (a/b) is the number of patients who had the event
of interest and have taken the drug of interest (a) divided
by the number of patients who had the event when taking
any other drug (b). Thus this gives the ratio of the drug
being taken, relative to all other drugs, for patients who had
the event of interest. This is then compared to an analogous
calculation for all other events, i.e. the number of patients
who have taken the drug of interest but did not have the event
of interest (c), divided by the number of people who had any
other events, given that they took any other drug (d).
The standard error (SE) for the ROR method is calculated
as follows:
SE(lnROR) =
√
1
a
+
1
b
+
1
c
+
1
d
(2)
where ‘ln’ denotes the natural logarithm. This equation is
used in the signal threshold calculation described below.
B. Proportional Reporting Ratio
The PRR on the other hand can be calculated as follows:
PRR =
a/(a + c)
b/(b + d)
(3)
where a/(a + c) can be thought of as the probability of
an event of interest occurring, given the drug of interest was
taken and an event occurred. b/(b+ d) can be thought of as
the probability that the event of interest occurred, given any
other drug was taken and an event occurred. Therefore the
PRR approximates the ratio of the conditional probabilities
for the event of interest, given the drug of interest and other
drugs or given the other drug.
The standard error (SE) for the PRR method is calculated
as follows:
SE(lnPRR) =
√
1
a
− 1
a + b
+
1
c
+
1
c + d
(4)
C. Standard Error of ROR and PRR
If the value of the ROR or PRR is larger than one, this
suggests that there is a deviation from the background rates
that are inferred by the frequency of events that occur for
drugs other than the drug of interest. The signal thresholds
for the ROR and PRR are ROR − 1.96 × SE > 1 and
PRR− 1.96× SE > 1 respectively [11]. These correspond
to the lowest value of the 95% confidence interval being
greater than 1.
Fig. 1. A patient time-line starting from the time the drug is taken, T0.
Tcrit is the time period chosen to find suspected drug-ADE relations and
Ei ∀i ∈ [1, n], n ∈ N are events that occur between T0 and Tcrit.
D. Database Pre-Processing
To calculate the ROR and PRR for the drugs and events
in the GP database first requires identifying suspected drug-
ADEs. This was done by finding events that occur within a
set time period after a drug is taken for each patient. The
time period used is Tcrit−T0 where T0 is the time at which
a drug is taken and Tcrit is a value defining the length of
the time window. A graphical representation of this can be
seen in Figure 1.
Two values of Tcrit are investigated, Tcrit = 2 months
and Tcrit = ∞. The Tcrit = 2 months was suggested by
a medical expert to predict immediately occurring ADEs as
people may not report events immediately but increasing the
time period further will introduce more noise. The Tcrit =∞
was investigated as this may help identify events that do not
occur immediately.
In the rest of this work, the dataset of potential adverse
events for each drug using the association Tcrit = 2 and
Tcrit = ∞ is defined as GP2 and GP∞ respectively. The
ROR and PRR and their respective standard errors are then
calculated using Equations (1) to (4) for these two datasets.
E. Receiver Operating Characteristic for the Comparison of
Medical Databases
The receiver operating characteristic (ROC) analysis was
chosen to investigate the suitability of applying the existing
methods to the GP database. A ROC analysis plots the true
positive rate (TPR) against the false positive rate (FPR),
where these are defined in Equations (5) and (6). In our
scenario the TPR is the amount of correctly identified adverse
events divided by the number of adverse events. A FPR is one
minus the number of correctly identified non-adverse events
divided by the number of non-adverse events. The higher the
value of the false positive rate, the more noisy the result. A
method with such properties is naturally of little practical
use.
TPR =
A
A + C
(5)
FPR = 1− D
B + D
(6)
The existing methods have been successfully implemented
on the SRS database in the past. By comparing the ROC
plots of the methods on the SRS database with that of the
GP database may give some indication of the suitability of
applying the methods to the GP database. For each method
the true positive rate and false positive rate are calculated
using the values describe in Table 2 over a range of signal
threshold values.
Known Not known Total
side effect side effect
Signaled A B A+B
Not signaled C D C+D
Total A+C B+D N=A+B+C+D
TABLE II
VALUES USED TO CALCULATE THE TRUE POSITIVE AND FALSE POSITIVE
RATES USED IN THE ROC ANALYSIS.
1) Hierarchical Structures in Databases: Some medical
databases employ a structure in the way medical events
are recorded. The GP database used in this work has a
hierarchical structure for reported events. A typical event Ej
is represented by a code x1x2x3x4x5 where xi ∈ {0} ∪
N≤9 ∪{a-z}∪{A-Z}∪{•}. An example of an event code is
“AB1a•”. The level of an event can be calculated as follows:
L(E) =
{
arg min
i
{(i− 1)| xi = •} if ∃ i s.t. xi = •
5 otherwise
(7)
The above given example event is reported at level 4. The
higher the level, the greater the detail known about an event.
A level 4 event x1x2x3x4• is a more detailed version of a
level 3 event x1x2x3•• . It can also be seen that a patient who
has an event x1x2x3x4• also must have the event x1x2x3 ••
.
The ROC analysis requires the knowledge of known
adverse events. The known adverse events used are those
listed as possible side effects in the BNF [10]. For each of
the known adverse events, the set of event codes relating
to event Ej is found and denoted Kj . For example if an
event of interest is “nausea”, all event codes related to this
event are contained in the set K1. These event codes however
also range over the hierarchal levels. It is thus common
in the GP database for each of the known adverse events,
Kj , j ∈ [1, n], where n denotes the number of adverse
events, to have different cardinalities.
The function I defined below finds the number of known
adverse events that have at least one of the associated event
codes signaled by the data-mining technique. The purpose of
the I function is to find a fair way of determining the TPR
of the methods when each Kj have different cardinalities.
I(Kj) =
{
1 if Kj ∩ S 6= ∅
0 if Kj ∩ S = ∅ (8)
Letting K =
⋃
j Kj denote the set of all known adverse
event codes, S denotes the set of all signaled event codes, Ω
the set of all event codes and | | the cardinality of a set.
The values A,B,C and D in Table 2 are found by:
A =
n∑
j=1
I(Kj) (9)
B = |S ∩Kc| (10)
C = n−
n∑
j=1
I(Kj) (11)
D = |Sc ∩Kc| (12)
where Kc is the complement of K. This is equal to Ω \
K, which can be stated as the sample space less K. Sc is
analogous to Kc.
III. EXPERIMENTAL SETUP
In the performed experiments two different databases, GP
Database and SRS Database, are investigated using the two
different methods, namely ROR and PRR.
A. General Practice Database
The two databases investigated in this paper are the
GP database containing complete records of patients while
registered at a UK general practice. These records include
medical events, drugs prescribed, family histories, general
demographics and patient information. The patient informa-
tion contains useful data such as date of birth, gender, date of
registration and if present, date of death. Every time a patient
visits the surgery a record will be added to the database
regarding events relating to that visit. Entering the data
is compulsory. The GP database studied contains medical
records for a total of 69616 patients. These records span over
a 107 year time-period from 1902 until 2010 and contain
1,858,229 medical events and 678,159 drug prescriptions.
B. Spontaneous Reporting System Database
The SRS database studied in this paper is the US Food
and Drug Administration (FDA) Adverse Event Reporting
System (AERS). The database contains information on pos-
sible drug-ADE interactions. Included in the database is
information regarding the drug taken, the possible adverse
drug event, the general outcome of the drug and the patient
information, including demographics. The data is recorded by
professionals or the general public when a suspected drug-
ADE has occurred, however not all information is always
included. Often records are incomplete and mistakes can be
made. This type of database is also prone to under reporting.
The time period for the records investigated range from first
quarter of 2004 to the second quarter of 2009. The total
number of drugs sequences reported is 6,354,539 and the
total number of unique events names recorded is 14,064. For
the general patient information 51% of the records contain
missing information either regarding the patients age, gender
or event date. Gender is only recorded 94% of the time and
age 64% of the time.
C. Tested Hypotheses
The following null hypotheses, along with their alterna-
tives, are investigated in this paper:
ROR/PRR ROC (Segment) Comparison:
H0: There is no statistically significant difference between
the areas under the receiver operating characteristic curve
(for the FPR less than n%) calculated by applying the
ROR/PRR on the GP and SRS databases.
H1: There is a statistically significant difference between
the areas under the receiver operating characteristic curve
(for the FPR less than n%) calculated by applying the
ROR/PRR on the GP and SRS databases.
The ROC segment comparison is investigated (n < 100)
as the method performance is only relevant for low FPR’s. A
large FPR means that the actual adverse events found would
be swamped by an excess amount of non-adverse events that
are essentially noise. As the maximum number of events in
the three datasets is approximately 14, 000, the value n =
0.02 is investigated. This means the maximum number of
false positive signals is less than 300 and therefore less that
ten times the number of actual adverse events for one of the
investigated drugs.
The hypotheses are tested by first mapping the GP data
into a structure suitable for the application of the ROR
and PRR methods. Different criteria for the mapping are
investigated. The ROR and PRR are performed on both
databases for two chosen drugs of interest. The drugs of
interest are Ethinylestradiol and Amoxicillin.
Once the ROR and PRR are calculated a ROC plot is
produced by investigating the true positive and true negative
rates form the signals produced using the thresholds: ROR ≥
n, n ∈ [0,∞) and PRR ≥ n, n ∈ [0,∞). This shows
the trade off between the number of true positives against
the number of false positives as the threshold becomes less
stringent.
The area under the curve (AUC) is calculated numerically
for all ROC plots. The AUC’s for the ROR and PRR applied
to the different databases are then tested for significant
differences by the methods described in [8]. The statistical
analysis for the AUC of the ROC segment is calculated in a
similar manner.
D. Investigated Drugs
1) Ethinylestradiol: Ethinylestradiol is a commonly used
drug found in the combined oral contraceptive pill.
Ethinylestradiol has been around for more than half a century
and the possible side effects have been well studied [10].
Recently there has been interest in a possible connection
between Ethinylestradiol and idiopathic venous thromboem-
bolic events [7].
2) Amoxicillin: Amoxicillin is a frequently used penicillin
based antibiotic that had the greatest number of prescriptions
within the GP database. It has been in use for almost four
decades [3]. As these drugs have been around for many
years and are frequently used, known side effects have
been observed and reported, including: nausea, vomiting,
diarrhoea, rashes and less commonly, antibiotic-associated
colitis [1].
IV. RESULTS
A total of 14,064, 10,755 and 9,158 possible adverse
events were found in the SRS database, GP with Tcrit =∞
and GP with Tcrit = 2 respectively.
A. Ethinylestradiol
The ROC plots, shown in Figures 2(a) and 2(b), illustrate
that the maximum TPR for both the ROR and PRR are
similar when applied to the three datasets. It is also apparent
that the TPR increases rapidly for all three datasets between
FPR values 0 and 0.1. Between FPR values 0.1 and 0.2 the
methods applied to the SRS database give the greatest TPR.
For values of FPR greater than 0.3 the database returning the
highest values of TPR is GP∞.
The AUC over the whole range of FPR for the application
of the ROR method with their corresponding 95% confidence
interval are: 0.73 (0.63-0.83), 0.77 (0.68-0.87) and 0.77
(0.67-0.86) for GP2, GP∞ and SRS respectively. Therefore
overall the ROC performed the worse on the GP2 dataset.
The AUC values for the GP2 and GP∞ were not significantly
different to that of the SRS, with corresponding p-values of
0.31 and 0.46. Leading to the rejection of the alternative
hypothesis.
The PRR gave similar results of 0.74 (0.70-0.79), 0.79
(0.69-0.88) and 0.77 (0.67-0.86) for the GP2, GP∞ and SRS
respectively. Again, the AUC values for the general practice
datasets where not significantly different to the AUC value
of the SRS.
The AUC values and the 95% confidence intervals for the
ROR over the FPR range of 0 to 0.02 were 0.0034 (0.0020-
0.0048) and 0.0012 (0.0006- 0.0017) for the GP∞ and SRS
respectively. The test for statistical similarity returned a p-
value of 0.002. Therefore we reject the null hypothesis that
the AUC values are the same between the GP dataset and the
SRS dataset. The corresponding values for the PRR method
were 0.0021 (0.0011- 0.0030) and 0.0002 (3.2 ×10−6 -
0.0003) for the GP∞ and SRS respectively. The p-value
for the statistical test for similarity between the two AUC
values is 0.00058. Again, this leads to the rejection of the
null hypothesis that the AUC values obtained by applying
the methods to the GP and SRS database are the same for
small FPRs.
When applying the general signal threshold criteria,
ROR − 1.96 × SE > 1 or PRR − 1.96 × SE > 1, the
ROR and PRR applied to the GP database with Tcrit = ∞
found the highest number of known adverse drug events, 17
and 19 respectively.
B. Amoxicillin
The Amoxicillin ROC analysis for both the ROR and PRR
is shown in Figures IV-B and ??. The PRR and ROR gave
similar ROC plots for Amoxicillin. For this drug, in all cases,
the null hypothesis could not be rejected. This implies that
statistically there exists no significant difference between the
results. From the figures it can be seen that for low values of
FPR the standard methods applied to the SRS dataset give
better results than for the GP database, however, using the
SRS dataset the methods cannot detect all adverse events
correctly. On the contrary, the GP dataset allows for the
correct detection of true adverse events whilst the number
FPR value increases.
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(a) ROC analysis for ROR
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(b) ROC analysis of PRR
Fig. 2. ROC analysis of Ethinylestradiol. Results for both the ROR and the PRR methods on the three tested datasets are shown.
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Fig. 3. The Amoxicillin ROC analysis for the ROR. It is apparent that the
standard methods applied to the SRS database produce better results when
the FPR is low, however with this database it is impossible for the standard
methods to achieve high levels of TPR. The PRR produced visually identical
results.
Overall the GP2 dataset had a greatest AUC. Applying the
existing methods to the SRS dataset gave the worse results in
terms of known adverse drug events found as can be seen in
Table III. Using the standard signal criteria, ROR− 1.96×
SE > 1 or PRR − 1.96 × SE > 1, the PRR applied to
the GP∞ dataset however detected all five known adverse
events.
V. DISCUSSION
The better results obtained from the standard methods
applied to the GP datasets over the SRS database in the
segment ROC analysis for Ethinylestradiol suggests that the
GP database contains at least as good information as the SRS
database in this case. The result for Amoxicillin on the other
hand reveals an interesting phenomenon of the GP database.
The SRS database does not contain enough information in
order to allow the standard methods to successfully detect all
potential adverse events. The GP datasets on the other hand
allow for the detection of all adverse events, however only
under the condition of having high FPR. This suggests that
the broader scope of the GP database offers potential benefits,
however in order to be able to obtain these, methods which
can reduce FPR need to be developed.
The result in the Amoxicilin case may be due to the
way potential adverse events are found via the GP database.
As mentioned in the introduction, some events that occur
frequently after the drug is taken may be related to the
event that caused the drug or be a seasonal effect. This
could cause the frequency of the specific drug and event
to be higher relative to the rest of the drugs and events,
even though they are not directly linked. Because of this,
the ROR may produce many false positives. Ethinylestradiol
is frequently taken as a monthly repeat prescription. This
means the time window that events must occur within, to
be considered potentially adverse, can last for years. This
longer time window may help to average out the effects of
events indirectly linked to the drug and therefore reduces the
amount of false positives.
The obtained results show that applying the ROR and
PRR on the GP database may help identify new signals. The
known adverse events detected for each drug differ between
all three datasets. Many of the known adverse events were
unable to be identified using the standard signal criteria for
the SRS. However, these were often found when using the
GP database. It is worth mentioning that although applying
the existing methods to the GP database for Ethinylestradiol
resulted in more known adverse event signals, as mentioned
above there were also more false positive signals. As the
ROC plots show all three datasets have similar sensitivity
and specificity associations. This suggests a different signal
criteria needs to be implemented when applying the existing
methods to the GP database.
The current method of applying the existing data-mining
Adverse Event ROR (GP) ROR (SRS) PRR (GP) PRR (SRS)
Tcrit = 2 Tcrit =∞ Tcrit = 2 Tcrit =∞
Nausea × × × × X ×
Vomiting X X X X X X
Diarrhoea X X × X X ×
Rash X X X X X X
Colitis × X X × X X
TABLE III
TABLE INDICATING IF THE METHOD WAS ABLE TO DETECT KNOWN ADVERSE EVENTS OF AMOXICILLIN WITH SIGNAL CRITERIA
ROR− 1.96× SE > 1 OR PRR− 1.96× SE > 1.
techniques to the GP database did not consider the potential
benefit of having a multiple level hierarchy for the event
codes. Rather than calculating the ROR for all the event
codes, it may be beneficial to apply the ROR separately
for each of the levels. It may be common for doctors to
record events as less specific than actually known. This may
prevent signals for specific adverse events being detected.
For example, the fifth level adverse event ‘reduced menstrual
loss’ may be frequently recorded as the fourth level ‘change
in menstrual loss’. The method implemented in this paper
would not have detected ‘change in menstrual loss’ as a
known signal. The reason being, higher level event codes
of known adverse events were not considered to be known
adverse event codes. However, calculating the ROR for level
four event codes may give a signal for ‘change in menstrual
loss’ which could then be considered a possible signal for
related level five event codes such as ‘reduced menstrual
loss’. These level five event codes could then be further
investigated with a case control analysis.
VI. CONCLUSIONS
In this work we have investigated the applicability of two
standard data-mining techniques for the detection of potential
adverse drug events in two different medical databases. The
spontaneous reporting system database provides a library of
suspected adverse events, however with limited information
and issues, such as under-reporting. Methods developed for
this type of database are limited by the quality and scope
of the data that the database provides. On the other hand
the general practice database provides a more comprehensive
medical record of patients that includes complete patient
history and thus provides greater possibilities for finding true
potential adverse events. Initially a method for transforming
the general practice database into a form processable by
the standard techniques has been proposed. Statistical tests
have been subsequently used to investigate whether results
obtained on the two different datasets are the same. The
null hypothesis in the case of comparing the entire receiver
operating characteristic curves was not rejected, however
looking at the vital part of the curve, with false positive
rates less than 2%, the null hypothesis was rejected and it
has been shown that the standard methods can perform better
on the general practice database. This suggests that new
techniques need to be developed in order to fully utilize the
information contained within the general practice database,
resulting in potentially more accurate adverse drug event
reporting. Beside the utilization of a wider variety of existing
information in the general practice database for analysis,
the hierarchical structure of the event coding system should
be considered in order to help with issues such as under-
reporting and missing information.
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